My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    Blonanserin (AD-5423)
    Blonanserin (AD-5423)

    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V1021
    CAS #: 132810-10-7Purity ≥98%

    Description: Blonanserin (formerly AD 5423; AD-5423; AD5423) is an atypical antipsychotic agent acting as a relatively selective serotonin (5-HT)2A and dopamine D2 antagonist with the potential to be used for the treatment of schizophrenia. Compare to many other antipsychotics, blonanserin has an improved tolerability profile, lacking side effects such as extrapyramidal symptoms, excessive sedation, or hypotension. As with many 2nd-generation (atypical) antipsychotics, Blonanserin is significantly more efficacious in the treatment of the negative symptoms of schizophrenia compared to 1st-generation (typical) antipsychotics such as haloperidol.

    References: Eur J Pharmacol. 2011 Feb 25;653(1-3):47-57; Behav Brain Res. 2013 Jun 15;247:158-64.

    Related CAS #: 132812-45-4 (HCl); 132810-10-7 (free base); 132812-47-6 (citrate)

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)367.5 
    CAS No.132810-10-7 
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: N/A
    Water: <1 mg/mL
    Ethanol: <1 mg/mL 
    Other info

    Chemical Name: 2-(4-ethylpiperazin-1-yl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine.


    InChi Code: InChI=1S/C23H30FN3/c1-2-26-13-15-27(16-14-26)23-17-21(18-9-11-19(24)12-10-18)20-7-5-3-4-6-8-22(20)25-23/h9-12,17H,2-8,13-16H2,1H3


    SynonymsAD 5423; AD-5423; AD5423;    

    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      • V1
      • C2
      • V2
    In Vitro

    In vitro activity: Blonanserin transiently increases neuronal firing in locus coeruleus and ventral tegmental area but not in dorsal raphe nucleus or mediodorsal thalamic nucleus, whereas Risperidone increases the firing in locus coeruleus, ventral tegmental area and dorsal raphe nucleus but not in mediodorsal thalamic nucleus of rats. Blonanserin persistently increases frontal extracellular levels of norepinephrine and dopamine but not serotonin, GABA or glutamate, whereas Risperidone persistently increases those of norepinephrine, dopamine and serotonin but not GABA or glutamate. Blonanserin increases the efflux of cortical DA and its metabolites, homovanillic acid and 3,4-dihydroxyphenylacetic acid. Blonanserin shows the most potent binding affinity for human D3 receptors among the tested atypical antipsychotics (risperidone, olanzapine and aripiprazole). Blonanserin acts as a potent full antagonist for human D3 receptors. Blonanserin blocks the binding of [(3)H]-(+)-PHNO, a D2/D3 receptor radiotracer, both in the D2 receptor-rich region (striatum) and the D3 receptor-rich region (cerebellum lobes 9 and 10). Blonanserin, a novel atypical antipsychotic agent with dopamine D(2)/serotonin 5-HT(2A) antagonistic properties, displays good brain distribution.

    In VivoBlonanserin, 1 mg/kg, but not 0.3 mg/kg, improves the PCP-induced NOR deficit in rats. Blonanserin significantly reverses the NOR deficit without diminishing activity during the acquisition or retention periods in rats. 
    Animal modelRats
    Formulation & Dosage1 mg/kg, but not 0.3 mg/kg

    Eur J Pharmacol. 2011 Feb 25;653(1-3):47-57; Behav Brain Res. 2013 Jun 15;247:158-64. 

    These protocols are for reference only. InvivoChem does not independently validate these methods.


      Home Prev Next Last page / pices


      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      Do you confirm the receipt?